BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37458396)

  • 1. Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    Wang A; Luo X; Meng X; Lu Z; Chen K; Yang Y
    J Med Chem; 2023 Jul; 66(14):9972-9991. PubMed ID: 37458396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
    Wang A; Luo X; Wang Y; Meng X; Lu Z; Yang Y
    J Med Chem; 2022 Sep; 65(18):12460-12481. PubMed ID: 36070471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
    Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
    Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
    Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
    Xu P; Yang JC; Ning S; Chen B; Nip C; Wei Q; Liu L; Johnson OT; Gao AC; Gestwicki JE; Evans CP; Liu C
    Pharmacol Res; 2023 Mar; 189():106692. PubMed ID: 36773708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
    Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
    Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
    Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
    Elife; 2023 Jan; 12():. PubMed ID: 36656639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.
    Shin WS; Han SH; Jo KW; Cho Y; Kim KT
    Sci Rep; 2023 Oct; 13(1):16663. PubMed ID: 37794090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC; Attard G
    Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
    Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.